A.R.T. Advisors’s Niagen Bioscience NAGE Stock Holding History

A.R.T. Advisors’s Portfolio NAGE Stock Details NAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-21,771	Closed	-$93K	–	1718
2018 Q3	$93K	Buy	+21,771	New	+$93.6K	﹤0.01%	1284

Other funds holding NAGE

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Iconiq Capital San Francisco, California $4.46B AUM 22.86% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TCM

Tieton Capital Management Yakima, Washington $299M AUM 54.55% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JMPWA

JP Morgan Private Wealth Advisors San Francisco, California $35B AUM 24.26% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

A.R.T. Advisors's NAGE Position: Q4 2018 in Review

A.R.T. Advisors sold out of Niagen Bioscience (NAGE) in Q4 2018, closing a stake of 21,771 shares — an estimated $93K sold.

A.R.T. Advisors first reported a position in NAGE in Q3 2018 and held it in 1 quarter. The position peaked at $93K in Q3 2018. 61 funds tracked by Wall St. Rank hold NAGE as of Q4 2018.

A.R.T. Advisors reported no remaining Niagen Bioscience position as of Q4 2018 after selling out during the quarter.
A.R.T. Advisors sold 21,771 Niagen Bioscience shares in Q4 2018, an estimated $93K.
A.R.T. Advisors first reported a position in Niagen Bioscience in Q3 2018 and held it in 1 quarter.
A.R.T. Advisors's Niagen Bioscience position peaked at $93K in Q3 2018.
61 funds tracked by Wall St. Rank held Niagen Bioscience as of Q4 2018.

Based on A.R.T. Advisors's 13F filing for Q4 2018, filed 14 Feb 2019.